The Impact of Botox on Neuroimmune Interactions in Atopic Dermatitis
ConditionAtopic Dermatitis (AD)
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorDaniel Kaplan
About this trial
The purpose of this study is to understand cellular and molecular interactions in the skin of participants with mild-to-moderate AD, and how botulinum toxin alters these interactions.
Eligibility criteria
Qualifiers
Patients 18 years or older at time of consent
BSA ≤ 10%
IGA ≤ 3
No past biologic therapy
Disqualifiers
Age less than 18 years old
Pregnant or breastfeeding
Has medical comorbidity such as end stage congestive heart failure or coagulopathy that is a relative contradiction to skin biopsy procedure
Has had prior exposure to biologic treatments or has had prior treatment with systemic non-biologics (e.g. methotrexate) within 12 weeks
Trial design
Treatments tested in this trial
- Onabotulinum Toxin Type A - Phase 1b
- Onabotulinum Toxin Type A - Phase 2
Treatment groups
8 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov